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Abstract
Recent evidence suggests that the AKT1-GSK3b signalling cascade partially mediates dopamine-
dependent behaviours. In relation to the pathophysiology of schizophrenia or methamphetamine (Meth)
use disorder, AKT1 is a good candidate gene for such conditions. For schizophrenia, positive associations
of SNPs and AKT1 haplotypes were reported in US and Japanese samples. To evaluate the association
between AKT1 and Meth-use disorder, we conducted a case-control study of Japanese samples (182
patients and 437 controls). A positive association between a SNP and haplotypes was found, and the
‘signal’ SNP was the same SNP found to be associated with US schizophrenia, but not with Japanese
schizophrenia. Our results indicate that AKT1 may play a possible role in the development of Meth-use
disorder. Further investigation of these associations, together with evidence from previous animal studies,
may open the way to elucidation of the pathophysiology of this condition.
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Introduction
The pathophysiology of methamphetamine (Meth) use
disorder has not been well established, however, one
of the most likely mechanisms is abnormality of the
dopamine (DA) neurotransmission system. The phar-
macological proﬁle of Meth shows that the target
site of Meth is the DA transporter (DAT). Also the
mesolimbic DA system has an important function in
reinforcement and reward mechanisms (Spanagel and
Weiss, 1999).
Family and twin studies suggested that the genetic
contribution is important in that it may predispose
certain people to this disorder (Tsuang et al., 1996,
1998). Recent studies have suggested that V-akt
murine thymoma viral oncogene homologue 1 (AKT1)
is a good candidate for a Meth-use disorder suscep-
tibility gene, for the following reasons. (1) An animal
study of DAT knock-out (KO) mice and wild-type
mice, treated with lithium salts and amphetamine,
showed that the AKT1–glycogen synthase kinase 3b
(GSK3b) signalling cascade partially mediated
DA-dependent behaviours (Beaulieu et al., 2004). (2)
AKT1 KO mice treated with amphetamine showed a
reduction in prepulse inhibition (PPI) (Emamian et al.,
2004). PPI disturbances are known to be present
in schizophrenia, which might also be related to
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abnormalities in theDAsystem.AKT1haplotypeswere
shown to have a signiﬁcant association with schizo-
phrenia in a transmission disequilibrium test (TDT)
study (Emamian et al., 2004) and in a previous
Japanese case-control replication study by the authors
(Ikeda et al., 2004), although no association was found
in another Japanese replication study (Ohtsuki et al.,
2004).
Here we conducted a case-control study of Japanese
Meth-use disorder samples using the single nucleotide
polymorphisms (SNPs) of our previous study to evalu-
ate the association of AKT1 with Meth-use disorder.
Methods
A total of 182 patients with Japanese Meth-use
disorder [146 male, 36 female; mean age¡standard
deviation (S.D.), 36.7¡12.0 yr] and 437 controls (209
male, 228 female; 34.3¡13.6 yr) were analysed. The
number of patients with Meth-use disorder comprised
of 168 Meth-dependent subjects, and 14 Meth-abuse
subjects. Among the subjects with Meth-use disorder,
153 subjects (127 males, 26 females) have a comorbid
diagnosis of Meth-induced psychosis, three of anor-
exia nervosa, one of obsessive–compulsive disorder,
and one of major depressive disorder. And 120
subjects with Meth-use disorder have abuse or
dependence on drugs other than Meth. Subjects
with Meth-use disorder were excluded if they had
a comorbid diagnosis of any psychotic disorder other
than Meth-induced psychosis. They were diagnosed
according to DSM-IV criteria by the consensus of at
least two experienced psychiatrists on the basis of
unstructured interviews and review of the medical
records. All healthy controls were also psychiatrically
screened based on unstructured interviews. More
details about the characterization of these subjects
have been published elsewhere (Suzuki et al., 2003;
Ujike et al., 2003). After description of the study,
written informed consent was obtained from each
subject. This study was approved by the Ethics
Committee at each participating institute of the
Japanese Genetics Initiative for Drug Abuse (JGIDA).
For SNP genotyping, polymerase chain reaction
(PCR) ampliﬁcation, restriction fragment length
polymorphism (RFLP) assays were developed; BsaI
for SNP1 (rs3803300), XcmI for SNP2 (rs1130214),
HaeIII for SNP3 (rs3730358), HpyCH4IV for SNP4
(rs2498799), PstI for SNP5 (rs2494732), and BsiHKAI
for SNPA (rs2498804). A detailed description may be
found in a previous report (Ikeda et al., 2004) and
information about primer sequences and PCR–RFLP
conditions are available on request.
Hardy–Weinberg equilibrium (HWE) was eval-
uated by conventional x2 test (SPSS 10.0J, SPSS Japan
Inc., Tokyo, Japan). For marker-trait association
analyses, we constructed multi-SNP haplotype
systems (Emamian et al., 2004) to evaluate the associ-
ation through permutation p values in sliding window
fashion and global p values respectively. In total
sample association analysis (not in explorative associ-
ation analysis), we emphasize the permutation p values
over the respective global p values because the
permutation procedure gives a signiﬁcance corrected
for the multiple haplotypes and markers tested.
Furthermore, we corrected these permutation p values
by Bonferroni correction to obtain more robust results.
A more detailed description is given in our previous
paper (Ikeda et al., 2004).
We also include an explorative analysis for gender
eﬀects, because of the following reasons. (1)
Aetiological study suggests that the genetic contri-
bution of substance-related disorder is diﬀerentially
heritable by gender (Jang et al., 1997). (2) Our samples
were unmatched gender ratios of Meth-use disorder
(36 female, 146 male).
Results
Genotype frequencies of all SNPs were in HWE.
Positive permutation p values of 4- and 5-marker
sliding window fashion (p=0.0083 and 0.023 respect-
ively) and global p value of 6-marker combinations
(p=0.017) were obtained. One of the 4-marker sliding
window fashion p values remained signiﬁcant
(p=0.0498) even after Bonferroni correction was per-
formed six times (once for single marker permutation
and ﬁve times for haplotype combinations). In the
single marker association analysis (i.e. a conventional
allele-wise association analysis), only SNP3was associ-
ated with Meth-use disorder (p=0.019) (Table 1).
Individual haplotypic analyses from the positive
global 4-marker p values are shown in Table 2. The
haplotype with the most signiﬁcant association was
more frequent in controls than in cases (SNP1-2-3-4,
G-G-C-G, p=0.0032).
Explorative analysis of gender eﬀects is shown in
Table 3. In female samples, eight of 21 global p values
showed signiﬁcance. In these signiﬁcant p values,
SNP3, which was associated with total Meth-use
disorder, showed strong association (p=0.0011). On
the other hand, the positive global p values in male
samples tended to be similar to those in total samples
(positive global p values: SNP1-2-3-4=0.036, SNP1-2-
3-4-5-A=0.042), however, SNP3 was not associated
with male Meth-use disorder (p=0.11).
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Discussion
Apositive association between a SNP andAKT1 haplo-
types was found in our Japanese Meth-use disorder
samples. In assessing the components of these associ-
ations, we considered SNP3 to be a main component
associated with Meth-use disorder, because the single
marker association of SNP3 was signiﬁcant in total
samples (p=0.019). Interestingly, this SNP was associ-
ated with US schizophrenia in an original TDT
analysis (Emamian et al., 2004). On the contrary, we
found no association SNP3 to Japanese schizophrenia
in a previous study (SNP5 was associated with
Japanese schizophrenia) (Ikeda et al., 2004). This
diﬀerence in predisposing SNPs between Japanese
Meth-use disorder and Japanese schizophrenia
might be explained by their respective linkage dis-
equilibrium (LD) patterns. We have shown that the LD
pattern in schizophrenia was slightly diﬀerent from
that in controls, while the pattern inMeth-use disorder
tended to be similar to that in control samples (data
not shown). These ﬁndings indicate that diﬀerent
predisposing polymorphisms may exist indepen-
dently in schizophrenia and Meth-use disorder, and
may be located in LD with SNP5 or SNP3 respectively.
The result of explorative analysis might support the
‘gender eﬀects’ of Meth-use disorder, reported in a
previous genetic association study of Meth-use dis-
order (Lin et al., 2003). Especially, female samples of
Table 1. Association analyses of the AKT1 gene
SNP ID
Genotypic distribution
Multi-SNP haplotype systems M/M M/m m/m
1 SNP 2 SNP 3 SNP 4 SNP 5 SNP 6 SNP Meth Control Meth Control Meth Control
SNP1
(rs3803300G>A)
0.15 63 124 91 234 28 79
0.22
SNP2
(rs1130214G>T)
0.97 0.096 128 315 51 108 3 14
0.27 0.0023
SNP3
(rs3730358C>T)
0.019 0.43 0.0082 136 364 43 68 3 5
0.12 0.23 0.017 (0.10)
SNP4
(rs2498799G>A)
0.81 0.11 0.16 40 121 98 211 44 105
0.53 0.063
SNP5
(rs2494732A>G)
0.59 0.19 86 212 79 192 17 33
0.16
SNPA
(rs2498804T>G)
0.20 63 142 92 206 27 89
Permutation 0.097 0.40 0.28 0.0083 0.023
p value (0.0498) (0.14)
p values were calculated by log likelihood ratio test (SNP1, allele-wise association; SNP2-6, global haplotypic association).
M, major allele ; m, minor allele; Meth, methamphetamine-use disorder.
Bold values represent signiﬁcant p values.
Values within parentheses represent p values after Bonferroni correction.
Table 2. Haplotype frequencies from positive permutation
analysis
Combination
of SNPs
Marker
haplotype
Frequency
p valuesMeth Control
SNP1-2-3-4 A-G-C-G 0.28 0.20 0.023
A-G-T-A 0.074 0.048 0.049
G-G-C-G 0.12 0.21 0.0032
Meth, Methamphetamine-use disorder.
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Meth-use disorder were strongly associated with a
SNP and haplotypes of AKT1, while male samples
were weakly associated. However, because the sample
size of female subjects was small (n=36), a type I error
might occur in this explorative analysis. Even
assuming that there are no ‘gender eﬀects’ of AKT1,
the fact remains that AKT1 is associated with Meth-
use disorder. In this case, these association analyses of
total and divided samples indicate the following
interpretations. (1) SNP3 might not be an ‘actual’
predisposing SNP by itself, nor be in perfect LD with
‘actual ’ predisposing polymorphisms, because male
samples with Meth-use disorder were not associated
with SNP3 (only total or female samples were asso-
ciated with it). (2) At least some haplotypes of AKT1
may play a possible role in the development of Meth-
use disorder, because two haplotypes of AKT1,
including the combination of SNP1-2-3-4 and SNP 1-2-
3-4-5-A, are associated with Meth-use disorder both in
divided samples and total samples.
Our results had several limitations in terms of
interpreting positive associations. (1) The positive
associations we detected might be due to type I error,
possibly because of population stratiﬁcation, an un-
matched-gender sample and small sample size, de-
scribed above. Larger sample size and genomic control
would be required. (2) Type I error might also have
occurred because of multiple testing. We corrected
p values by applying a permutation procedure and
Bonferroni correction in total samples. However, in
individual haplotypic analysis or explorative analysis
of gender eﬀects, we did not apply each correction.
At this time, an optimal method for resolving this
problem (correction among global and individual
haplotypic analysis, or explorative-subgroup analysis)
has not yet been established. Greater knowledge of
genetic models and more useful methods would be
required to re-analyse these results. (3) The other
confounding factors such as ascertainment bias can
account for the apparent association in this study. For
example, because subjects with Meth-induced psy-
chosis consisted of the majority of our samples, this
condition would be over-represented in our samples
of Meth-use disorder. Further explanation is given in
Nishiyama et al. (2005).
Our results indicate that AKT1 may play a role in
the development of Meth-use disorder. Our ﬁndings
also support the hypothesis that abnormalities in
AKT1 might contribute to the pathophysiology of
DA-dependent behaviour such as Meth-use disorder
and schizophrenia. Further studies including mu-
tation search to detect ‘actual ’ predisposing poly-
morphisms and functional analysis of AKT1 (or its
cascade) may open the way to elucidation of the
pathophysiology of this condition.
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